↓ Skip to main content

Evolocumab: First Global Approval

Overview of attention for article published in Drugs, September 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

twitter
1 X user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
41 Mendeley
Title
Evolocumab: First Global Approval
Published in
Drugs, September 2015
DOI 10.1007/s40265-015-0460-4
Pubmed ID
Authors

Anthony Markham

Abstract

Evolocumab (Repatha™) is a fully human monoclonal antibody developed by Amgen that has been approved as a treatment for hypercholesterolaemia in the EU, and is awaiting approval in the USA and Japan. It specifically binds proprotein convertase subtilisin/kexin type 9 (PCSK9)-a negative regulator of low-density lipoprotein (LDL)-receptors-thereby improving the ability of the liver to bind LDL-cholesterol (LDL-C), leading to reduced LDL-C blood levels. The drug reduces LDL-C levels in patients with hypercholesterolaemia when used as monotherapy or in conjunction with a statin. This article summarizes the milestones in the development of evolocumab leading to this approval for the treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet with or without a statin and/or other lipid lowering therapies, and in adults and adolescents aged ≥12 years with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
New Zealand 1 2%
Netherlands 1 2%
Unknown 39 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 20%
Researcher 7 17%
Student > Ph. D. Student 6 15%
Student > Bachelor 4 10%
Student > Postgraduate 4 10%
Other 4 10%
Unknown 8 20%
Readers by discipline Count As %
Medicine and Dentistry 18 44%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Biochemistry, Genetics and Molecular Biology 3 7%
Agricultural and Biological Sciences 2 5%
Nursing and Health Professions 1 2%
Other 2 5%
Unknown 11 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2015.
All research outputs
#6,961,201
of 22,826,360 outputs
Outputs from Drugs
#1,204
of 3,254 outputs
Outputs of similar age
#82,208
of 266,863 outputs
Outputs of similar age from Drugs
#16
of 38 outputs
Altmetric has tracked 22,826,360 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 3,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,863 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.